FDA Approves Generic Lenacapavir to Expand Global HIV Prevention
The US FDA has approved a generic version of the twice-yearly HIV prevention injection Lenacapavir, aiming to provide affordable treatment in 120 low- and middle-income countries for roughly 40 dollars a year.
The US Food and Drug Administration (FDA) has approved a generic version of Lenacapavir, the world's only twice-yearly injectable drug for HIV prevention. This milestone marks a major step toward making the treatment rapidly accessible and affordable across 120 low- and middle-income nations.
Pricing and Global Impact
Estimates indicate the medication will cost roughly 40 dollars per person annually in target countries, matching the price of existing daily preventative pills. However, injections offer significantly higher convenience due to their low frequency. Two groundbreaking trials involving high-risk populations showed the injections were nearly 100 percent effective in blocking new infections.
"People do not always adhere to taking a daily pill, and if you miss doses, you are not protected against HIV," explained Carmen Perez Casas, head of the HIV team at the global health agency Unitaid. Health advocates emphasize that over the long term, the therapy is expected to sharply reduce infection rates, morbidity, and mortality.
Regulatory Status and Production
According to World Health Organization (WHO) figures, approximately 41 million people live with HIV globally, while half a million died from virus-related causes last year. The new generic version will not be sold in the United States, where the original brand, Yeztugo, manufactured by Gilead Sciences, remains patent-protected with an annual list price exceeding 28,000 dollars.
The tentative FDA approval utilizes a longstanding pathway designed to guarantee the quality of HIV medications distributed abroad by the US government. The generic version was developed by India-based Dr. Reddy's Laboratories under agreements mediated by Unitaid, the Clinton Health Access Initiative, and the African research institute Wits RHI. Local health authorities note that routine HIV testing remains mandatory prior to administration to prevent drug resistance.
